Antimicrobial Resistance: Causes, Risks, and the Threat of Superbugs

The World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the top three major public health threats globally. This phenomenon occurs when bacteria, viruses, fungi, and parasites evolve over time, rendering existing medicines ineffective and making infections significantly harder to treat.

According to the WHO, this resistance increases the risk of disease spread, severe illness, and death. The misuse and overuse of antimicrobials across humans, animals, and plants serve as the primary drivers in the development of these drug-resistant pathogens.

The Role of Food and Environment in AMR Spread

Antimicrobial-resistant germs do not remain confined to clinical settings; they spread through the community, the environment, and the food supply. The Centers for Disease Control and Prevention (CDC) noted on September 25, 2025, that these germs move between healthcare facilities and the general population.

The spread of resistance is facilitated by the movement of people, animals, and goods. With more than one billion people moving globally, including 410 million travelers arriving in the U.S. Through over 300 points of entry annually, antimicrobial-resistant threats can spread rapidly across borders.

Transmission can occur through several pathways, including person-to-person activities such as handshaking, attending school, working out, or having sex. Resistance also spreads between humans and animals, including pets and those found in petting zoos.

International travel further complicates the issue, as individuals may acquire infections from contaminated food or water, other people, animals, or by receiving medical care in regions where certain resistant germs are more common.

Impact on Modern Medicine and Public Health

AMR threatens the viability of many achievements in modern medicine. When infections become resistant to treatment, standard medical procedures become significantly riskier. The WHO identifies surgery, cancer chemotherapy, and caesarean sections as treatments that are put at higher risk by the prevalence of AMR.

The human cost of this trend is substantial. The WHO estimates that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to a total of 4.95 million deaths that year.

While AMR affects all regions and income levels, it is exacerbated by inequality and poverty. Low- and middle-income countries are the most severely affected by the drivers and consequences of these resistant pathogens.

Economic Consequences and the Research Gap

Beyond the immediate health crisis, AMR carries heavy economic burdens. The World Bank estimates that by 2030, AMR could result in annual gross domestic product (GDP) losses ranging from US$ 1 trillion to US$ 3.4 trillion.

the World Bank projects that antimicrobial resistance could lead to US$ 1 trillion in additional healthcare costs by 2050.

These challenges are compounded by what the WHO describes as an antibiotics pipeline and access crisis. There is currently an inadequate research and development pipeline to create new medicines in the face of rising resistance levels.

There is an urgent requirement for measures to ensure equitable access to existing and new diagnostics, vaccines, and medicines to combat the surge of superbugs.

Prevention and Mitigation Strategies

To protect public health, it is critical to slow the development of resistance and stop the spread of existing resistant germs. The CDC suggests that simple interventions can be effective in slowing the spread of these threats.

• Maintaining good hygiene practices.
• Following routine vaccination schedules.
• Practicing safer sex.
• Ensuring safe food preparation.

On a systemic level, the WHO outlines several priorities to address AMR in human health. These include preventing infections to reduce the inappropriate use of antimicrobials and ensuring universal access to quality diagnosis and appropriate treatment.

Strategic innovation is also required, specifically through the surveillance of antimicrobial consumption and the research and development of novel medicines, diagnostics, and vaccines.